NDAORALTABLET
Approved
Jan 2009
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
SAVELLA (milnacipran hydrochloride) by AbbVie is unknown. Approved for fibromyalgia (). First approved in 2009.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SAVELLA (milnacipran hydrochloride) is an oral tablet approved by the FDA in January 2009 for the treatment of fibromyalgia. It functions as a serotonin-norepinephrine reuptake inhibitor (SNRI), with approximately 3-fold higher potency for norepinephrine reuptake compared to serotonin reuptake in vitro. The exact mechanism by which milnacipran alleviates fibromyalgia symptoms remains unknown, though preclinical studies demonstrate potent inhibition of neuronal norepinephrine and serotonin reuptake without affecting dopamine or other neurotransmitter systems.
$0.1BPart D
3.4 years to LOEMechanism of Action
unknown. Preclinical studies have shown that milnacipran is a potent inhibitor of neuronal norepinephrine and serotonin reuptake; milnacipran inhibits norepinephrine uptake with approximately 3-fold higher potency in vitro than serotonin without directly affecting the uptake of dopamine or other…
Indications (1)
Clinical Trials (1)
The Savella Pregnancy Registry
Started Nov 2009
350 enrolled
Fibromyalgia
Worked on SAVELLA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.